Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement

BP Lee, K Witkiewitz, J Mellinger, FA Anania… - Nature Reviews …, 2024‏ - nature.com
Most patients with alcohol-associated liver disease (ALD) engage in heavy drinking defined
as 4 or more drinks per day (56 g) or 8 (112 g) or more drinks per week for women and 5 or …

Inflammation in alcohol-associated hepatitis: pathogenesis and therapeutic targets

D Feng, S Hwang, A Guillot, Y Wang, Y Guan… - Cellular and Molecular …, 2024‏ - Elsevier
Alcohol-associated hepatitis (AH) is an acute-on-chronic liver injury that occurs in patients
with chronic alcohol-associated liver disease (ALD). Patients with severe AH have high short …

[HTML][HTML] Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives

M Yan, S Man, L Ma, L Guo, L Huang… - Clinical and Molecular …, 2024‏ - pmc.ncbi.nlm.nih.gov
Steatotic liver diseases (SLD) are the principal worldwide cause of cirrhosis and end-stage
liver cancer, affecting nearly a quarter of the global population. SLD includes metabolic …

Alcohol-Associated liver disease: Emerging therapeutic strategies

BH Mullish, MR Thursz - Hepatology, 2024‏ - journals.lww.com
The large and growing burden of alcohol-associated liver disease—and the considerable
burden of morbidity and mortality associated with it—has been a drive toward ongoing …

Larsucosterol for the treatment of alcohol-associated hepatitis

M Shiffman, B Da, A Goel, A Kwong, L Stein… - NEJM …, 2025‏ - evidence.nejm.org
Background Larsucosterol is a DNA methyltransferase inhibitor in development for alcohol-
associated hepatitis (AH), a disease for which there is no approved therapy. Methods In this …

Acute kidney injury in severe alcohol-associated hepatitis treated with anakinra plus zinc or prednisone

KR Patidar, W Tu, TG Cotter, DA Simonetto… - Hepatology, 2024‏ - journals.lww.com
Acute Kidney Injury in Severe Alcohol-Associated Hepatitis Treated with Anakinra plus Zinc or
Prednisone Kavish R. Patidar1,2, W Page 1 Acute Kidney Injury in Severe Alcohol-Associated …

Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models

X Hong, S Huang, H Jiang, Q Ma, J Qiu… - Frontiers in …, 2024‏ - frontiersin.org
Alcohol-related liver disease (ALD) is a major cause of morbidity and mortality worldwide. It
encompasses conditions such as fatty liver, alcoholic hepatitis, chronic hepatitis with liver …

[HTML][HTML] Infections in decompensated cirrhosis: Pathophysiology, management, and research agenda

JF Toll, E Solà, MA Perez, S Piano… - Hepatology …, 2024‏ - journals.lww.com
Bacterial infections in patients with cirrhosis lead to a 4-fold increase in mortality. Immune
dysfunction in cirrhosis further increases the risk of bacterial infections, in addition to …

Research Priorities and Future Landscape of Clinical Trials in Alcohol-Associated Liver Disease

AV Kulkarni, AK Singal, PS Kamath - Clinics in liver disease, 2024‏ - liver.theclinics.com
Research Priorities and Future Landscape of Clinical Trials in Alcohol-Associated Liver
Disease - Clinics in Liver Disease Skip to Main Content Skip to Main Menu Advertisement …

Corticosteroids in severe alcohol-associated hepatitis? Not so fast: A systematic review of randomized controlled trials

MA Shi, P Pungwe, LLM Comer, M Balakrishnan… - Hepatology, 2025‏ - journals.lww.com
Background: Severe alcohol-associated hepatitis (AH) is rising in incidence with a high
mortality burden. While corticosteroids are recommended for eligible patients with severe …